Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort

R. Salle, F. Tubach, H. Arlegui, R. Curmin, M. Viguier, M. Beylot-Barry, A. Dupuy, N. Beneton, P. Joly, Y. De Rycke, D. Jullien, E. Mahé, C. Paul, M.-A. Richard, H. Bachelez, M. Zago, O. Chosidow, É. Sbidian and the PSOBIOTEQ study group

Clinical and Experimental Dermatology 2023

Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort

H. Arlegui, E. Mahé, M.-A. Richard, Y. De Rycke, M. Viguier, M. Beylot-Barry, A. Dupuy, N. Beneton, P. Joly, D. Jullien, H. Bachelez, É. Sbidian, O. Chosidow, C. Paul, F. Tubach and the PSOBIOTEQ study group

ADV 2023

Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry

H. Aubert, H. Arlegui, Y. De Rycke, H. Bachelez, M. Beylot-Barry, A. Dupuy, P. Joly, D. Jullien, E. Mahé, C. Paul, MA. Richard, E. Sbidian, M. Viguier, O. Chosidow, F. Tubach, N. Bénéton and the PsoBioTeq Study Group

BJD 2023

Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.

R. Curmin, S. Guillo, Y. De Rycke, H. Bachelez, M. Beylot-Barry, N. Beneton, O. Chosidow, A. Dupuy, P. Joly, D. Jullien, M.-A. Richard, M. Viguier, E. Sbidian, C. Paul, E. Mahé, F. Tubach and the PSOBIOTEQ study group

JEADV 2022

Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood

E. Mahé, F. Tubach, D. Jullien, C. Paul, M. Beylot-Barry, A. Dupuy, M. Viguier, M-A. Richard, E. Sbidian, N. Beneton, P. Joly, O. Chosidow, H. Bachelez and PSOBIOTEQ Registry investigators.

ACTA DV 2022

Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort

T. Bettuzzi, H. Bachelez, M. Beylot-Barry, H. Arlégui, C. Paul, M. Viguier, E. Mahé, N. Beneton, D. Jullien, M-A. Richard, P. Joly, F. Tubach, A. Dupuy, E. Sbidian, O. Chosidow and the PSOBIOTEQ study group

ACTA DV 2022

Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort

M. Beylot-Barry, J. Seneschal, M-H-T. Diep Tran, H. Bachelez, N. Beneton, A. Dupuy, P. Joly,D. Jullien, E. Mahé, C. Paul, M-A. Richard, E. Sbidian, M. Viguier, O. Chosidow and F. Tubach

BJD 2021

First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.

F. Assan, F. Tubach, H. Arlegui, M. Viguier, M. Beylot-Barry, A. Dupuy, N. Beneton, P.l Joly, D. Jullien, E. Mahé, C. Paul, M-A. Richard, H. Bachelez, C. Giboin, O. Chosidow, E. Sbidian and the PSOBIOTEQ Study Group.

Dermatology  2021

Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.

M. Masson Regnault, J. Castañeda-Sanabria, M-H-T. Diep Tran, M. Beylot-Barry, H. Bachelez, N. Beneton, O. Chosidow, A. Dupuy, P. Joly, D. Jullien, E. Mahé, M-A. Richard, M. Viguier, F. Tubach, E. Sbidian, C. Paul and the PSOBIOTEQ Study Group

JEADV 2019

Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.

E. Sbidian, C. Giboin, H. Bachelez, C. Paul, M. Beylot-Barry, A. Dupuy, M.Viguier, J-P. Lacour, J-L. Schmutz, P. Bravard, E. Mahé, N. Beneton, L. Misery, E. Delaporte, P. Modiano, S. Barbarot, E. Regnier, D. Jullien, M-A. Richard, P. Joly, F. Tubach and O. Chosidow.

JEADV 2017